Header

UZH-Logo

Maintenance Infos

Publications for Ascierto, P A

Navigate back| Up a level
Export as
Group by:
Number of items: 16.

2017

Chapman, P B; Robert, C; Larkin, J; Haanen, J B; Ribas, A; Hogg, D; Hamid, O; Ascierto, P A; Testori, A; Lorigan, P C; Dummer, R; Sosman, J A; Flaherty, K T; Chang, I; Coleman, S; Caro, I; Hauschild, A; McArthur, G A (2017). Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Annals of Oncology, 28(10):2581-2587.

Coens, Corneel; Suciu, Stefan; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Celeste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Bottomley, Andrew; Kotapati, Srividya; de Pril, Veerle; Testori, Alessandro; Eggermont, Alexander M M (2017). Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncology, 18(3):393-403.

Dummer, Reinhard; Schadendorf, Dirk; Ascierto, Paolo A; Arance, Ana; Dutriaux, Caroline; Di Giacomo, Anna Maria; Rutkowski, Piotr; Del Vecchio, Michele; Gutzmer, Ralf; Mandala, Mario; Thomas, Luc; Demidov, Lev; Garbe, Claus; Hogg, David; Liszkay, Gabriella; Queirolo, Paola; Wasserman, Ernesto; Ford, James; Weill, Marine; Sirulnik, L Andres; Jehl, Valentine; Bozón, Viviana; Long, Georgina V; Flaherty, Keith (2017). Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 18(4):435-445.

2016

Ascierto, Paolo A; Agarwala, Sanjiv; Botti, Gerardo; et al (2016). Future perspectives in melanoma research: meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. Journal of Translational Medicine, 14:313.

Eggermont, Alexander M M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Céleste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Bastholt, Lars; Mortier, Laurent; Thomas, Luc; Tahir, Saad; Hauschild, Axel; Hassel, Jessica C; Hodi, F Stephen; Taitt, Corina; de Pril, Veerle; de Schaetzen, Gaetan; Suciu, Stefan; Testori, Alessandro (2016). Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. New England Journal of Medicine, 375(19):1845-1855.

Lacouture, Mario E; Dréno, Brigitte; Ascierto, Paolo Antonio; Dummer, Reinhard; Basset-Seguin, Nicole; Fife, Kate; Ernst, Scott; Licitra, Lisa; Neves, Rogerio I; Peris, Ketty; Puig, Susana; Sokolof, Jonas; Sekulic, Aleksandar; Hauschild, Axel; Kunstfeld, Rainer (2016). Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. The oncologist, 21(10):1218-1229.

2015

Dummer, Reinhard; Schadendorf, Dirk; Ascierto, Paolo A; Larkin, James; Lebbé, Celeste; Hauschild, Axel (2015). Integrating first-line treatment options into clinical practice: what's new in advanced melanoma? Melanoma research, 25(6):461-469.

Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentler, Thomas K; Gangadhar, Tara C; Carlino, Matteo S; Agarwala, Sanjiv S; Moschos, Stergios J; Sosman, Jeffrey A; Goldinger, Simone M; Shapira-Frommer, Ronnie; Gonzalez, Rene; Kirkwood, John M; Wolchok, Jedd D; Eggermont, Alexander; Li, Xiaoyun Nicole; Zhou, Wei; Zernhelt, Adriane M; Lis, Joy; Ebbinghaus, Scot; Kang, S Peter; Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16(8):908-918.

Larkin, James; Chiarion-Sileni, Vanna; Gonzalez, Rene; Grob, Jean Jacques; Cowey, C Lance; Lao, Christopher D; Schadendorf, Dirk; Dummer, Reinhard; Smylie, Michael; Rutkowski, Piotr; Ferrucci, Pier F; Hill, Andrew; Wagstaff, John; Carlino, Matteo S; Haanen, John B; Maio, Michele; Marquez-Rodas, Ivan; McArthur, Grant A; Ascierto, Paolo A; Long, Georgina V; Callahan, Margaret K; Postow, Michael A; Grossmann, Kenneth; Sznol, Mario; Dreno, Brigitte; Bastholt, Lars; Yang, Arvin; Rollin, Linda M; Horak, Christine; Hodi, F Stephen; Wolchok, Jedd D (2015). Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine, 373(1):23-34.

Basset-Seguin, Nicole; Hauschild, Axel; Grob, Jean-Jacques; Kunstfeld, Rainer; Dréno, Brigitte; Mortier, Laurent; Ascierto, Paolo A; Licitra, Lisa; Dutriaux, Caroline; Thomas, Luc; Jouary, Thomas; Meyer, Nicolas; Guillot, Bernard; Dummer, Reinhard; Fife, Kate; Ernst, D Scott; Williams, Sarah; Fittipaldo, Alberto; Xynos, Ioannis; Hansson, Johan (2015). Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncology, 16(6):729-736.

Eggermont, Alexander M M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Céleste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Konto, Cyril; Hoos, Axel; de Pril, Veerle; Gurunath, Ravichandra Karra; de Schaetzen, Gaetan; Suciu, Stefan; Testori, Alessandro (2015). Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncology, 16(5):522-530.

Lorigan, Paul; Ascierto, Paolo A; Dummer, Reinhard; Eggermont, Alexander M; Flaherty, Keith T; Garbe, Claus; Gogas, Helen; Hauschild, Axel; Kefford, Richard F; Kirkwood, John M; Larkin, James; Long, Georgina V; Maio, Michele; McArthur, Grant A; Ribas, Antoni; Robert, Caroline; Schadendorf, Dirk; Sondak, Vernon K; Wolchok, Jedd D; Hudson, Andrew M (2015). Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncology, 16(1):15-17.

Ascierto, Paolo A; Atkins, Michael; Bifulco, Carlo; Botti, Gerardo; Cochran, Alistair; Davies, Michael; Demaria, Sandra; Dummer, Reinhard; Ferrone, Soldano; Formenti, Silvia; Gajewski, Thomas F; Garbe, Claus; Khleif, Samir; Kiessling, Rolf; Lo, Roger; Lorigan, Paul; Arthur, Grant Mc; Masucci, Giuseppe; Melero, Ignacio; Mihm, Martin; Palmieri, Giuseppe; Parmiani, Giorgio; Puzanov, Igor; Romero, Pedro; Schilling, Bastian; Seliger, Barbara; Stroncek, David; Taube, Janis; Tomei, Sara; Zarour, Hassane M; Testori, Alessandro; Wang, Ena; Galon, Jérôme; Ciliberto, Gennaro; Mozzillo, Nicola; Marincola, Francesco M; Thurin, Magdalena (2015). Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014. Journal of Translational Medicine, 13(1):online.

2014

McArthur, Grant A; Chapman, Paul B; Robert, Caroline; Larkin, James; Haanen, John B; Dummer, Reinhard; Ribas, Antoni; Hogg, David; Hamid, Omid; Ascierto, Paolo A; Garbe, Claus; Testori, Alessandro; Maio, Michele; Lorigan, Paul; Lebbé, Celeste; Jouary, Thomas; Schadendorf, Dirk; O'Day, Stephen J; Kirkwood, John M; Eggermont, Alexander M; Dréno, Brigitte; Sosman, Jeffrey A; Flaherty, Keith T; Yin, Ming; Caro, Ivor; Cheng, Suzanne; Trunzer, Kerstin; Hauschild, Axel (2014). Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncology, 15(3):323-332.

Flaherty, Keith T; Hennig, Michael; Lee, Sandra J; Ascierto, Paolo A; Dummer, Reinhard; Eggermont, Alexander M M; Hauschild, Axel; Kefford, Richard; Kirkwood, John M; Long, Georgina V; Lorigan, Paul; Mackensen, Andreas; McArthur, Grant; O'Day, Steven; Patel, Poulam M; Robert, Caroline; Schadendorf, Dirk (2014). Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncology, 15(3):297-304.

2013

Ascierto, Paolo A; Schadendorf, Dirk; Berking, Carola; Agarwala, Sanjiv S; van Herpen, Carla Ml; Queirolo, Paola; Blank, Christian U; Hauschild, Axel; Beck, J Thaddeus; St-Pierre, Annie; Niazi, Faiz; Wandel, Simon; Peters, Malte; Zubel, Angela; Dummer, Reinhard (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncology, 14(3):249-256.

This list was generated on Fri Oct 20 12:48:03 2017 CEST.